Navigation Links
New Heart Ultrasound Research Reveals Life-Saving Treatment Alternatives and Advancements for Heart Patients
Date:6/8/2009

Breakthrough findings unveiled at the American Society of Echocardiography's Scientific Sessions

WASHINGTON, June 8 /PRNewswire/ -- The American Society of Echocardiography (ASE) welcomes the world's leading researchers in cardiovascular medicine to present their most-recent findings at its 20th Annual Scientific Sessions, June 6-10, at the Gaylord National Convention Center in Washington, DC. This year, NBA basketball player and former heart patient, Ronny Turiaf will be in attendance to talk about how echocardiography, otherwise known as heart ultrasound, saved his life.

Many of the studies revealed will have a significant impact on the diagnosis and treatment of heart disease and the application of echocardiograms. Studies detail the following:

  • A nonsurgical option for common heart procedures
  • Lack of adherence to guidelines leave symptoms unidentified and patients untreated
  • Newer technology that can better predict survival chances for heart patients

To view the full text of the press releases and study abstracts, please visit SeeMyHeart.org.

NONSURGICAL OPTION FOR COMMON HEART PROCEDURE OFFERS EFFECTIVE RESULTS WITH LESS RECOVERY TIME FOR PATIENTS

Technique presents options to elderly patients who may not survive open-heart surgery

This study found that patients unable to undergo open-heart surgery may be candidates for a new nonsurgical aortic valve replacement procedure. Transcatheter aortic valve replacement is a promising new treatment for patients with severe aortic stenosis who are considered high risk for conventional surgical aortic valve replacement.

With this approach, echocardiography, or heart ultrasound, is used to guide interventional cardiologists through the procedure and to assess the effects
'/>"/>

SOURCE The American Society of Echocardiography
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Many Heart Attack Patients Dont Get Best Emergency Treatment
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?
4. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
5. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
6. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
7. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
8. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
9. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
10. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
11. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,, IRVINE,Calif.,Nov.24/PRNewswire-FirstCall...llyinvasivetreatmentsforaorticdisorders,announcedt...oceedingsin,thepatentinfringementlawsuitbroughtaga...heUnitedStatesDistrictCourtinIndianapolis,Indiana....ectwhiletheUnitedStatesPatentandTrademarkOffice(US...
(Date:11/24/2009)...,, WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNew...heU.S.FoodandDrugAdministration(FDA)hasacceptedfor...mgAricept®(donepezilHClextendedrelease)tablet...se(AD).Thisnewhigherdoseformulationcontains23mgofd...thadeliverysystemthatallowsforgradualreleaseofthed...
(Date:11/24/2009)...,, STAMFORD,Conn.,Nov.24/PRNewswire/--Zargis...E )andaspin-offfromSiemensCorporateResearch(NYSE: ...sfeaturedontheNovember24,2009episodeofCBS, TheEarl...PopularScience magazine,reviewedfivewinningproduct...,, TheEarlyShow isawidely-viewedtelevisionmorn...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 1Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 2Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 1Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 1Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 3Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 4
...INESS WIRE)--Apr 16, 2007 - Amgen,(Nasdaq:AMGN) to...e-blind, placebo-controlled Phase 3 study evaluati...tin alfa) for the,treatment of anemia in patients ...adiotherapy ("the 103 study"). Aranesp is not,appr... These,results were presented in an oral session a...
...primary endpoint not met; plausibly,confounded by ...TUX,-, NEW YORK, April 16, 2007 /PRNewswire-FirstC...yers Squibb Company today,announced detailed resul... multi-center Phase III trial - comparing ERBITUX(... in patients with,metastatic colorectal cancer (mC...
Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
(Date:11/25/2009)...survivors of testicular cancer who were treated wi...de effects, including neurological side effects an...eated with chemotherapy, according to a new study ...e National Cancer Institute . , Marianne Brydy, ...versity Hospital, in Bergen, Norway, and colleague...
(Date:11/25/2009)...lready used to fight rheumatoid arthritis, could h... , WEDNESDAY, Nov. 25 (HealthDay News) -- A dr...nd rheumatoid arthritis now also shows some promis...diabetes. , The drug, rituximab (Rituxan), help...in, even though the disease had destroyed some of ...
(Date:11/25/2009)...ORK,Nov.25/PRNewswire/-- MISSIONSkincare ®isp...orSt.Jude.AspartofGNC,sannualSt.Jude ThanksandGivi...kincare,s new SUPER-C(TM)LipBalm willbedonatedto...ytomakea$1,$5or$10donationatcheckoutatoneoftheir5,...than$1millionforSt.Judeduringtheir2009 ThanksandGi...
(Date:11/25/2009)...s behavior problems that can occur in children wit...h a treatment plan that includes medication combin... according to Yale University researchers and thei...issue of the Journal of the American Academy of C...ducted by the National Institute of Mental Health ...
(Date:11/25/2009)... BioSpace.com, the premier resource f...the third edition of the BioForest™ Hotbed C...nglewood, CO (Vocus) November 25, 2009 -- BioSpace...s and information, unveiled the third edition of t... , , , ,This regional campaign is a promotional e...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2
...ull House and,Senate poised to vote on the Preside...horization bill, a five-year, $50 billion initiati...rldwide, Congress must address,the critical HIV pr... nearly two million more,people have access to ant...
...LY AGGRESSIVE VACCINATION SCHEDULE TO,COMBAT RISIN...children who,regressed into autism after receiving...vernment health officials may at last be catching ...nference call held earlier in March,bringing toget...
...tinue the habit after initial coil treatment surge...- Smokers with a brain aneurysm who are treated wi...tients to develop another aneurysm, according to a...the groin and then threaded to the affected area o...
...w medications longer, study finds , , FRID...second-generation antipsychotics are no better tha...pisode of schizophrenia, a new study finds. , Howe... we compared newer drugs to older drugs, we found ...
... T. Clark, Chief,Executive Officer and President o...eutical Research and Manufacturers of America (PhR...g. Also elected were AstraZeneca Chief,Executive O...asurer., In addition, PhRMA announced that Takeda...
...n German . , Boxing is possibly less dangerous ... amateurs. However, conclusive statements on the l...ssional boxers such as Muhammad Ali contracted the...il more extensive studies of both amateur and prof...
Other Medicine News:Health News:Will Congress Do More for HIV Prevention? 2Health News:Will Congress Do More for HIV Prevention? 3Health News:Will Congress Do More for HIV Prevention? 4Health News:MITOCHONDRIAL DYSFUNCTION, VACCINES AND AUTISM: 1 in 50 Children Could Be at Risk 2Health News:Smokers at Increased Risk of Aneurysm Recurrence 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 2Health News:New Drugs No Better Than Older Ones for Schizophrenia 3Health News:Richard T. Clark Elected PhRMA Board Chairman 2Health News:Richard T. Clark Elected PhRMA Board Chairman 3Health News:Richard T. Clark Elected PhRMA Board Chairman 4Health News:Richard T. Clark Elected PhRMA Board Chairman 5Health News:How dangerous is boxing for the brain? 2
Sophia Vest V-654
Gabrielle Vest V-650
Female Mini-VEST, Front Closure, X-Firm
Male Support Brief
Medicine Products: